CagriSema is a combination therapy of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist) developed by Novo Nordisk. Clinical trials have shown superior weight loss compared to either component alone.

In the REDEFINE 1 trial, CagriSema achieved approximately 22.7% mean body weight reduction at 68 weeks, outperforming semaglutide 2.4 mg alone (15.8%). It targets both GLP-1 and amylin pathways simultaneously.

CagriSema is administered as a single weekly subcutaneous injection containing fixed-ratio cagrilintide 2.4 mg and semaglutide 2.4 mg at maintenance dose, with a gradual dose escalation period. The calculator helps with research dosing calculations.